---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-007755"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T00:59:22.587803+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma receives U.S. patent covering SPC-15 for stress-induced affective disorders

## Summary
- USPTO issued U.S. Patent 11,491,120 for SPC-15, a prophylactic using ketamine for anxiety and PTSD in females.
- Patent protects method of treatment and prevention for stress-induced affective disorders including PTSD.
- Silo holds option to license assets from Columbia University including potential treatments for Alzheimer's disease.
- CEO Eric Weisblum highlighted scope of allowed claims and market potential for SPC-15.

## SEC filing metadata
- accession: 0001213900-23-007755
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390023007755/0001213900-23-007755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390023007755/ea172649-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-007755
- JSON: https://secwatch.observer/filing/0001213900-23-007755.json
- Plain text: https://secwatch.observer/filing/0001213900-23-007755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.